Analysts forecast that Urovant Sciences Ltd (NASDAQ:UROV) will announce ($1.36) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Urovant Sciences’ earnings, with the lowest EPS estimate coming in at ($1.45) and the highest estimate coming in at ($1.29). Urovant Sciences posted earnings per share of ($0.94) in the same quarter last year, which would indicate a negative year-over-year growth rate of 44.7%. The firm is expected to announce its next earnings results on Tuesday, August 11th.
According to Zacks, analysts expect that Urovant Sciences will report full year earnings of ($6.88) per share for the current fiscal year, with EPS estimates ranging from ($7.62) to ($6.38). For the next fiscal year, analysts anticipate that the business will report earnings of ($5.34) per share, with EPS estimates ranging from ($5.68) to ($4.99). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that follow Urovant Sciences.
Urovant Sciences (NASDAQ:UROV) last posted its quarterly earnings results on Thursday, June 18th. The company reported ($1.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.25) by ($0.43).
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Trust Advisors LP lifted its position in shares of Urovant Sciences by 8.1% during the second quarter. First Trust Advisors LP now owns 15,299 shares of the company’s stock worth $151,000 after purchasing an additional 1,144 shares during the last quarter. Vigilare Wealth Management bought a new position in shares of Urovant Sciences during the second quarter worth about $100,000. Royal Bank of Canada lifted its position in shares of Urovant Sciences by 2,950.8% during the first quarter. Royal Bank of Canada now owns 9,305 shares of the company’s stock worth $86,000 after purchasing an additional 9,000 shares during the last quarter. Alyeska Investment Group L.P. lifted its position in shares of Urovant Sciences by 171.9% during the first quarter. Alyeska Investment Group L.P. now owns 483,168 shares of the company’s stock worth $4,455,000 after purchasing an additional 305,437 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Urovant Sciences by 3.4% during the first quarter. Geode Capital Management LLC now owns 82,371 shares of the company’s stock worth $759,000 after purchasing an additional 2,715 shares during the last quarter. 23.81% of the stock is owned by institutional investors.
Shares of UROV traded down $0.28 during mid-day trading on Friday, reaching $8.14. 87,236 shares of the stock traded hands, compared to its average volume of 67,867. The stock has a fifty day simple moving average of $9.93 and a 200 day simple moving average of $10.45. Urovant Sciences has a 12-month low of $6.55 and a 12-month high of $15.98.
Urovant Sciences Company Profile
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Featured Article: Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.